Christopher Bebbington

Christopher Bebbington DPhil received a Bachelor of Arts in Natural Science from the University of Oxford, U.K. and a Master of Arts and Doctor of Philosophy also from the University of Oxford. He has more than 25 years experience in the biopharmaceutical industry. He held various scientific and leadership roles at Celltech Ltd, including Head of Mammalian Expression and Team leader in Immunomodulation. During this time, he developed expression systems for recombinant antibodies, including the GS-System™, used in the manufacture of several approved antibody products, and conducted research into T-cell activation and chimeric antigen receptors. He was Director of Molecular Immunology at Coulter Pharmaceutical Inc., Senior Director of Research at Corixa Corp. and led a team that transferred to Medarex Inc on the acquisition by Medarex of antibody-drug conjugate technology and assets from Corixa. In 2003 Dr Bebbington was a co-founder of Celscia Therapeutics, a therapeutic antibody development company which merged in 2004 to form KaloBios Pharmaceuticals Inc. At KaloBios he has served as Vice President of Research, leading a team that has developed a novel antibody humanization technology, “Antibody Humaneering™” and entered 4 engineered human antibodies into formal pre-clinical development with three antibodies currently in clinical trials.